Eventful Monday For AstraZeneca - What's Going On?

On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the CALYPSO Phase 3 trial designed to evaluate the efficacy and safety of eneboparatide in adults with chronic hypoparathyroidism.

The study showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical significance at 24 weeks in adults with chronic hypoparathyroidism (HypoPT) compared to placebo.

The primary endpoint is a composite of normalization of albumin-adjusted serum calcium levels and independence from active vitamin D and oral calcium therapy.

Also Read: AstraZeneca’s Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients

HypoPT is a rare endocrine disease caused by a deficiency of PTH and is characterized by impaired regulation of calcium and phosphate levels in the blood. Eneboparatide was ...